Global Cyclooxygenase 1 Inhibitor Market, By Application (Inflammatory Diseases, Gastrointestinal Toxicity, Others), Types (Selective Cox 1 Inhibitor, Non-Selective Cox 1 Inhibitor), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2031.
Cyclooxygenase 1 Inhibitor Market Analysis and Size
In 1991, Simmons and his colleagues recognized a second cyclooxygenase enzyme that is designated cyclooxygenase-2 and derived from a separate gene from cyclooxygenase-1. Increasing research regarding the use of cox 1 inhibitors and advanced technological features are primarily responsible for the growth of the cyclooxygenase 1 inhibitor market globally. Furthermore, the growing occurrence of cancer cases and neuro-inflammatory diseases can also increase the growth of this market.
Data Bridge Market Research analyzes that the global cyclooxygenase 1 inhibitor market which was USD 70,000.12 million in 2023, is expected to reach USD 120,145.42 million by 2031, and is expected to undergo a CAGR of 7.00% during the forecast period of 2024 to 2031. “Dried” dominates the product type segment of the market due to rising demand for cyclooxygenase 1 inhibitors. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cyclooxygenase 1 Inhibitor Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Application (Inflammatory Diseases, Gastrointestinal Toxicity, Others), Types (Selective Cox 1 Inhibitor, Non-Selective Cox 1 Inhibitor), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Jsn Technologies (U.K.), Boehringer Ingelheim International GmbH (Germany), Bayer AG (Germany), Sabinsa (U.S.), Cadila Pharmaceuticals. (India), Mylan N.V (U.S.), Alembic Pharmaceuticals Limited (India), Zydus Group (India), Aurobindo Pharma (India), Cipla Inc. (U.S.), Torrent Pharmaceuticals Ltd (India), Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (U.S.), Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Cyclooxygenase 1 inhibitors are a kind of non-steroidal anti-inflammatory drugs. Cyclooxygenase 1 is a type of enzyme that is primarily responsible for pain and inflammation. They are mainly responsible for the production of prostaglandins. The induction of COX2 during inflammation has caused the development of several nonselective therapeutic COX1 and COX2 inhibitors that include ibuprofen, ketoprofen, flurbiprofen, and fenoprofen.
Global Cyclooxygenase 1 Inhibitor Market Dynamics
Drivers
- Increasing Prevalence of Cancer
According to Cancer.org, men tend to have a 1 in 23 lifetime risk of having cancer, on the other hand, women have a 1 in 25. Cancer is the third most common cause of mortality in men and the second most common cancer in women. Around 1.8 million new cases were observed in 2018. Around 39% of cases are diagnosed at an early stage. The 5-year survival rate is nearly 71% if cancer locates to neighboring tissues, organs, or regional lymph nodes. Thus, this factor boosts the market growth.
- Increasing Healthcare Expenditure and Government Support
With the rising prevalence of cancer, the growing awareness for the disease and related treatment is also expanding. Government initiatives tend to offer better and more feasible treatments combined with favorable reimbursement policies which are expected to increase the industry growth. Moreover, increasing acceptance of advanced therapies such as Erbitux, Avastin, and Stivarga is expected to drive the market.
- Expanding Applications in Pain Management
COX-1 inhibitors play a crucial role in pain management, contributing to their prominence in the pharmaceutical market. Their effectiveness in alleviating various types of pain, including post-operative pain and chronic pain conditions, propels their widespread utilization. These inhibitors work by blocking the action of COX-1 enzymes, reducing the production of inflammatory mediators responsible for pain and discomfort. Their role in pain management extends across diverse medical specialties, making them an integral component of pain treatment regimens in orthopedics, neurology, and post-operative care. Their proven efficacy and established safety profile in managing pain position them as indispensable medications in the field of pain management, contributing significantly to their market growth.
Opportunities
- Personalized Medicine and Targeted Therapy
The shift toward personalized medicine and targeted therapies provides an opportunity to leverage COX-1 inhibitors in tailored treatment approaches. Advancements in genetic profiling and biomarker identification enable the identification of patient populations that might benefit most from COX-1 inhibitor therapy. Stratifying patients based on genetic predispositions or specific molecular profiles allows for more precise and targeted treatment strategies. Tailoring COX-1 inhibitor therapies to individual patient characteristics could improve treatment efficacy and minimize adverse effects, aligning with the trend toward personalized healthcare.
- Expanding Therapeutic Applications
Exploring new therapeutic applications for COX-1 inhibitors presents a promising opportunity in the market. While traditionally used for managing inflammation and pain, ongoing research investigates the potential of COX-1 inhibitors in other disease areas. Studies examining their role in cancer prevention, neuroprotection, and cardiovascular diseases offer avenues for expanding their therapeutic scope. Identifying and harnessing these novel applications may open new markets and avenues for COX-1 inhibitors, broadening their utility beyond traditional indications.
Restraints/Challenges
- Adverse Effects and Safety Concerns
Despite their therapeutic benefits, COX-1 inhibitors are associated with certain adverse effects and safety concerns, posing a significant restraint in their market growth. Prolonged use of these inhibitors may lead to gastrointestinal complications such as ulcers, bleeding, and perforation due to their interference with prostaglandin synthesis. The inhibition of COX-1 enzymes, responsible for maintaining gastric mucosal integrity, contributes to these adverse effects.
-
Patent Expirations and Generic Competition
The market for COX-1 inhibitors faces challenges due to patent expirations of key medications, leading to the entry of generic versions. The loss of patent exclusivity exposes original drug manufacturers to competition from generic drug manufacturers offering lower-cost alternatives. This scenario significantly impacts the revenue potential of branded COX-1 inhibitors, leading to market erosion and reduced profitability for originators.
This cyclooxygenase 1 inhibitor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclooxygenase 1 inhibitor market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2022, Dr. Reddy's laboratories launched the Ketorolac Tromethamine tablets USP, 10 mg, in the United States market. Ketorolac Tromethamine tablets, 10 mg, is a non-steroidal anti-inflammatory drug indicated for the short-term management of moderately severe acute pain
Global Cyclooxygenase 1 Inhibitor Market Scope
The cyclooxygenase 1 inhibitor market is segmented on the basis of application, types, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Inflammatory Diseases
- Gastrointestinal Toxicity
- Others
Types
- Selective Cox 1 Inhibitor
- Non-Selective Cox 1 Inhibitor
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Cyclooxygenase 1 Inhibitor Market Regional Analysis/Insights
The cyclooxygenase 1 inhibitor market is analyzed and market size insights and trends are provided by country, application, types, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.
Asia-Pacific is expected to exhibit the highest growth rate in the market during the forecast period of 2024 to 2031 due to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The cyclooxygenase 1 inhibitor market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cyclooxygenase 1 inhibitor market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cyclooxygenase 1 inhibitor market. The data is available for historic period 2011-2021.
Competitive Landscape and Global Cyclooxygenase 1 Inhibitor Market Share Analysis
The cyclooxygenase 1 inhibitor market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cyclooxygenase 1 inhibitor market.
Some of the major players operating in the cyclooxygenase 1 inhibitor market is:
- Jsn Technologies (U.K.)
- Boehringer Ingelheim International GmbH (Germany)
- Bayer AG (Germany)
- Sabinsa (U.S.)
- Cadila Pharmaceuticals. (India)
- Mylan N.V (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Zydus Group (India)
- Aurobindo Pharma (India)
- Cipla Inc. (U.S.)
- Torrent Pharmaceuticals Ltd (India)
- Abbvie, Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Pfizer Inc (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-